US Stock MarketDetailed Quotes
VNDA Vanda Pharmaceuticals
- 4.780
- +0.150+3.24%
Close Dec 20 16:00 ET
- 4.780
- 0.0000.00%
Post 20:01 ET
278.71MMarket Cap-16.48P/E (TTM)
4.830High4.590Low926.41KVolume4.590Open4.630Pre Close4.39MTurnover1.76%Turnover Ratio119.50P/E (Static)58.31MShares6.75052wk High0.51P/B251.53MFloat Cap3.46052wk Low--Dividend TTM52.62MShs Float33.440Historical High--Div YieldTTM5.18%Amplitude0.450Historical Low4.743Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Vanda Pharmaceuticals Stock Forum
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
Vanda Pharmaceuticals (VNDA) has received FDA Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide-based JAK2 inhibitor designed to treat polycythemia vera (PV). PV is a rare blood cancer affecting approximately 1 in 2000 Americans, characterized by excessive red...
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
Vanda Pharmaceuticals confirmed receipt of a second unsolicited, non-binding proposal from Cycle Group Holdings to acquire the company for $8.00 per share in cash. This proposal, received on September 23, 2024, is economically identical to the previously rejected offer from May 24, 2024.
Vanda's Board of Directors unanimously dete...
No comment yet